Completed PHASE4 INTERVENTIONAL 2-arm NCT00104104

A Multiple Myeloma Trial in Patients With Bone Metastases

A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases

Sponsor: Novartis Pharmaceuticals

Conditions Multiple Myeloma

Interventions zoledronic acid

Updated 6 times since 2017 Last updated: Jun 27, 2011 Started: Oct 31, 2004 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Appleton, United States , Augusta, United States , Bakersfield, United States , Bay Shore, United States , Bethesda, United States , Campbell, United States , Charleston, United States , Cherry Hill, United States , Clinton, United States and 54 more locations